Current Headlines
-
Ono Enters Into A Drug Discovery Collaboration And Option Agreement With Shattuck Labs To Generate Bifunctional Fusion Proteins
2/14/2024
Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that it has entered into a drug discovery collaboration and option agreement with Shattuck Labs, Inc. (Austin, Texas, USA; CEO: Taylor Schreiber; "Shattuck") to generate bifunctional fusion proteins for pathways involved in autoimmune and inflammatory diseases.
-
Edgewise Receives U.S. FDA Fast Track Designation For EDG-5506 For The Treatment Of Duchenne Muscular Dystrophy (Duchenne)
2/13/2024
Edgewise Therapeutics, Inc., a leading muscle disease biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDG-5506 for the treatment of Duchenne.
-
VantAI Enters Collaboration With Bristol Myers Squibb To Accelerate Molecular Glue Drug Discovery Through Artificial Intelligence
2/13/2024
VantAI, a company focused on generative AI-enabled drug discovery, and Bristol Myers Squibb a leading pharmaceutical company, have entered into a strategic collaboration to discover new molecular glues for therapeutic targets of interest.
-
Krystal Biotech Receives FDA Fast Track Designation For Inhaled Oncology Candidate KB707 To Treat Solid Tumors Of The Lung
2/13/2024
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for inhaled KB707 for the treatment of patients with solid tumors with pulmonary metastases that are relapsed or refractory to standard of care therapy.
-
CalciMedica Announces FDA Clearance Of IND Application For Phase 2 Trial Of Auxora™ For The Treatment Of Severe Acute Kidney Injury
2/13/2024
CalciMedica, Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases, today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for the Company's lead product candidate, Auxora™, a potent and selective small molecule inhibitor of Orai1-containing CRAC channels, to be evaluated in a Phase 2 trial in acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF).
-
High Content Screening For Biologics A Revolutionary Approach To Drug Discovery
2/13/2024
Heligenics, Inc., introduces a groundbreaking advancement in the discovery of new medicines. This cutting-edge research marks a pivotal moment in the field of biopharmaceuticals, in which High Content Screening, historically used for screening potential small molecule drugs, can now be applied to very important Biologic drugs such as Insulin, Interferons, and 100s of other medicines.
-
HTuO Biosciences Joins Johnson & Johnson Innovation - JLABS
2/12/2024
HTuO Biosciences, a biotechnology company developing an innovative molecular simulation platform for drug discovery, announces it has joined Johnson & Johnson Innovation - JLABS as a resident virtual company.
-
Iambic Therapeutics Announces New Research Published In Nature Machine Intelligence Demonstrating The Capabilities Of Its Generative AI Neuralplexer Technology To Predict Protein-Ligand Complex Structures
2/12/2024
Iambic Therapeutics, a biotechnology company developing novel therapeutics using its unique generative AI discovery platform, today announced the publication of research in Nature Machine Intelligence showing that its NeuralPLexer technology outperforms other state-of-the art systems in predicting the structure of protein-ligand complexes as well as the conformational changes to these structures from the addition of drug molecules.
-
Danaher Launches Collaboration With Cincinnati Children's Hospital Medical Center Aiming To Improve Patient Safety In Early Drug Development
2/7/2024
Danaher Corporation (NYSE: DHR), a global science and technology innovator, today launched a strategic collaboration with Cincinnati Children's Hospital Medical Center, with the goal of improving patient safety by addressing a leading cause of failure in clinical trials.
-
Chapman Scientists Code ChatGPT To Design New Medicine
2/7/2024
Generative artificial intelligence platforms, from ChatGPT to Midjourney, grabbed headlines in 2023. But GenAI can do more than create collaged images and help write emails — it can also design new drugs to treat disease.